Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% Premium

Brasil Notícia Notícia

Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% Premium
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 40 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 59%

American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manu...

Breaking

American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manufacturers struggle to keep up with the challenges of producing modern cancer treatments.Eli Lilly is purchasing the radiopharmaceutical company for $1.4 billion, or $12.

Point is developing radioligand therapies, a form of cancer treatment that delivers radiation directly to cancer cells and limits damage to the healthy surrounding tissue,Point is currently working on a drug called PNT2002 that aims to help advanced stage prostate cancer patients who are not responding to hormonal treatment.Eli Lilly broadened its cancer research efforts in 2019 when it purchased Loxo Oncology for $8 billion.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

ForbesTech /  🏆 318. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Eli Lilly gets FDA complete response letter for skin treatment after inspection of third-party facilityEli Lilly gets FDA complete response letter for skin treatment after inspection of third-party facilityEli Lilly & Co. said Monday the U.S. Food and Drug Administration has issued a complete response letter for its lebrikizumab, a treatment for...
Consulte Mais informação »

Eli Lilly Gets FDA Letter About Eczema Drug ConcernsEli Lilly Gets FDA Letter About Eczema Drug ConcernsThe pharmaceutical company says the letter cited no worries about the safety of its lebrikizumab skin treatment.
Consulte Mais informação »

Lilly to Buy Point Biopharma. Cancer-Treatment Stock Surges 84%.Lilly to Buy Point Biopharma. Cancer-Treatment Stock Surges 84%.Drug maker Eli Lilly agreed to acquire radiopharmaceutical company Point Biopharma Global for $12.50 a share.
Consulte Mais informação »

Drag queen comic donates wigs to give cancer survivors hope during Cancer Awareness Month'It makes me feel like myself,' one recipient said.
Consulte Mais informação »

Eli Lilly Gets FDA Letter About Eczema Drug Concerns. The Stock Shrugs.Eli Lilly Gets FDA Letter About Eczema Drug Concerns. The Stock Shrugs.The pharmaceutical company says the letter cited no worries about the safety of its lebrikizumab skin treatment.
Consulte Mais informação »

Eli Manning Shares a Strategy From His Parenting Playbook For Kids & Halloween CostumesEli Manning Shares a Strategy From His Parenting Playbook For Kids & Halloween CostumesIt may be a strategy in his playbook, but the former quarterback knows the plays don't always go as planned.
Consulte Mais informação »



Render Time: 2025-02-28 14:59:44